MiMedx Group (MDXG) Projected to Post Quarterly Earnings on Wednesday
MiMedx Group (MDXG) is scheduled to release its Q4 2025 earnings before market open on Wednesday, February 25th, with analysts forecasting earnings of $0.09 per share. The stock currently trades at $5.16, with a market cap of $764.2 million, and holds a "Moderate Buy" consensus rating among analysts, despite recent price target reductions. Institutional investors significant ownership of the company's shares.
MIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call on February 25
MIMEDX Group, Inc. (Nasdaq: MDXG) announced it will report its fourth quarter and full year 2025 operating and financial results after market close on February 25, 2026. The company's senior management team will host a webcast and conference call at 4:30 p.m. ET on the same day to discuss the results. A replay of the webcast will be available on the company's website for approximately 30 days.
MIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call on February 25
MiMedx Group, Inc. (Nasdaq: MDXG) announced it will host a conference call on February 25, 2026, to discuss its operating and financial results for the fourth quarter and full year ended December 31, 2025. The results will be released after market close, and the call will follow at 4:30 p.m. Eastern Time. Investors can access the webcast or dial in to the conference call to review the company's performance.
MiMedx Group, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
MiMedx Group, Inc. will release its fourth quarter and full-year 2025 financial results on February 25, 2026, after market close, followed by a conference call and webcast at 4:30 p.m. ET. The company, which specializes in healing solutions for chronic wounds, aims to provide transparency and insights into its performance for investors. The announcement also includes details on insider trading activity, revenue figures, hedge fund movements, and analyst ratings for MDXG.
MIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call on February 25
MIMEDX Group, Inc. has announced it will report its Q4 and full-year 2025 operating and financial results on Wednesday, February 25, 2026, after the market closes. The company's senior management team will host a webcast and conference call at 4:30 p.m. Eastern Time on the same day to review the results. MIMEDX is a leader in healing solutions, providing products for wound care, burn, and surgical sectors.
Northland Securities Comments on MiMedx Group Q1 Earnings
Northland Securities has revised its Q1 2026 EPS estimate for MiMedx Group (NASDAQ:MDXG) down to $0.00 from $0.02, while forecasting Q3 and Q4 EPS of $0.04 and $0.05, respectively. The company currently holds a "Moderate Buy" consensus rating with an average target price of $10.67, significantly above its current trading price of $5.03. MiMedx Group, a biopharmaceutical company specializing in regenerative biomaterial products, is characterized by a market cap of approximately $745 million and high institutional ownership.
MiMedx Strengthens Surgical Portfolio with Key Distribution Agreement
MiMedx Group, Inc. has entered into an exclusive distribution partnership with Summit Products Group for three FDA 510(k) cleared surgical wound care products: Hydrelix, NovaForm, and G4Derm Plus. This strategic move aims to expand MiMedx's commercial reach and reduce reliance on single product segments, especially in response to new U.S. healthcare regulations from CMS effective January 1. The company's fourth-quarter and full-year 2025 financial results, due February 25, are anticipated to reveal the impact of this new strategy.
MIMEDX Enters into Exclusive Distribution Agreement with Summit Products Group for Multiple Innovative Surgical & Wound Products
MIMEDX Group, Inc. has announced an exclusive distribution agreement with Summit Products Group for three new 510(k) cleared products: Hydrelix, NovaForm, and G4Derm Plus. These products, which include collagen matrix, bioglass and collagen-based wound dressing, and flowable peptide matrix, are designed to enhance MIMEDX's Surgical & Wound product portfolio. The partnership aims to strengthen MIMEDX's offering in the evolving surgical and wound care markets.
MDXG - Mimedx Group Inc Latest Stock News & Market Updates
This page provides the latest stock news and market updates for Mimedx Group Inc. (MDXG), a company specializing in regenerative medicine and advanced wound care. It covers announcements regarding new product launches, clinical milestones, financial results, and regulatory developments, offering investors comprehensive insights into the company's performance and strategy.
MDXG Stock Rises As MiMedx Enters Into Exclusive Distribution Agreement For Three Products
MiMedx Group Inc. (MDXG) shares rose approximately 5% after the company announced an exclusive distribution agreement with Summit Products Group for three of its 510(k) cleared products. These products, Hydrelix, NovaForm Wound Matrix, and G4Derm Plus, are designed to complement MiMedx’s existing portfolio for surgical and wound care markets. Retail sentiment on Stocktwits was bullish, with extremely high message volumes regarding the company.
MIMEDX Enters into Exclusive Distribution Agreement with Summit Products Group for Multiple Innovative Surgical & Wound Products
MIMEDX announced an exclusive distribution agreement with Summit Products Group for three innovative, 510(k) cleared products: Hydrelix, NovaForm, and G4Derm Plus. These products, which include a collagen powder, a bioglass and collagen-based wound dressing, and a flowable peptide matrix, are designed to enhance MIMEDX’s surgical and wound product portfolio. The agreement aims to strengthen MIMEDX’s position in the evolving surgical and wound markets.
MIMEDX signs exclusive distribution deal with Summit Products Group
MiMedx Group Inc. (MDXG) has entered into an exclusive distribution agreement with Summit Products Group to distribute three FDA 510(k) cleared surgical and wound care products: Hydrelix, NovaForm, and G4Derm Plus. This partnership will allow MIMEDX to expand its product offerings with xenograft and synthetic products in the surgical and wound care markets. Hydrelix is a sterile Type 1 collagen powder, NovaForm is a bioglass and collagen-based wound dressing, and G4Derm Plus is a flowable peptide matrix engineered for wound closure.
MIMEDX Enters into Exclusive Distribution Agreement with Summit Products Group for Multiple Innovative Surgical & Wound Products
MIMEDX has announced an exclusive distribution agreement with Summit Products Group for three new 510(k) cleared products: Hydrelix, NovaForm®, and G4Derm® Plus. These products, which include a collagen matrix, a bioglass and collagen-based wound dressing, and a flowable peptide matrix, will expand MIMEDX's offerings in the surgical and wound care markets. This partnership strengthens MIMEDX's portfolio with innovative xenograft and synthetic solutions, enhancing their ability to serve customers and patients.
MDXG Stock Rises As MiMedx Enters Into Exclusive Distribution Agreement For Three Products
MiMedx Group Inc. (MDXG) shares rose approximately 5% after the company announced an exclusive distribution agreement with Summit Products Group. Under this agreement, Summit will distribute three of MiMedx's 510(k) cleared products: Hydrelix, NovaForm Wound Matrix, and G4Derm Plus, all designed for wound care and closure. Despite this positive development, MDXG stock has seen significant declines over the past year.
MiMedx Group, Inc. Enters Exclusive Distribution Agreement with Summit Products Group for Innovative Wound Care Solutions
MiMedx Group, Inc. has announced an exclusive distribution agreement with Summit Products Group to distribute three new innovative wound care products: Hydrelix, NovaForm®, and G4Derm® Plus. These FDA-cleared products aim to expand MiMedx’s Surgical & Wound product portfolio and reinforce its position as a leader in the wound care market. The agreement expands their offerings with advanced solutions for various wound types, although financial projections or specific market expectations were not disclosed.
MIMEDX Enters into Exclusive Distribution Agreement with
MIMEDX has entered into an exclusive distribution agreement with Summit Products Group for three innovative surgical and wound products: Hydrelix, NovaForm®, and G4Derm® Plus. This partnership aims to expand MIMEDX's product offering in the Surgical & Wound markets with xenograft and synthetic solutions. The new products are designed to support wound healing through various mechanisms, including collagen matrices, bioglass dressings, and flowable peptide matrices.
MiMedx-Summit deal adds 3 products for ulcers and surgical wounds
MiMedx (MDXG) has signed an exclusive distribution agreement with Summit Products Group for three 510(k) cleared surgical and wound care products: Hydrelix, NovaForm, and G4Derm Plus. This deal, announced on February 4, 2026, expands MIMEDX's portfolio to include diverse wound treatment formats like powders, bioglass-collagen matrices, and flowable peptide matrices. Despite recent positive news, the company's stock has often shown muted or negative reactions.
MiMedx Group (NASDAQ:MDXG) Reaches New 52-Week Low - What's Next?
MiMedx Group (NASDAQ:MDXG) has hit a new 52-week low of $5.05 on heavy trading volume, with its stock currently trading below key moving averages. Despite a "Moderate Buy" consensus rating from analysts and an average target price of $10.67, several firms have recently lowered their price targets. Insider trading shows a sale of 58,300 shares by Kimberly Maersk-Moller in November, while institutional investors control a significant portion of the company's stock.
MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®
MiMedx Group, Inc. is celebrating the 15th anniversary of its flagship placental allograft products, EPIFIX and AMNIOFIX, which are used in wound care and surgical recovery. These products are recognized as the industry's most studied placental allografts, having been featured in nearly 100 clinical and scientific publications, including seven randomized controlled trials. The company credits its dedicated employees for reaching this significant milestone in pioneering innovation.
MiMedx Group, Inc. Enters Exclusive Distribution Agreement with Summit Products Group for Innovative Wound Care Solutions
MiMedx Group, Inc. has announced an exclusive distribution agreement with Summit Products Group to distribute three new innovative wound care products: Hydrelix, NovaForm®, and G4Derm® Plus. These FDA-cleared products are designed to enhance MiMedx’s Surgical & Wound product portfolio, offering advanced solutions for various types of wounds by promoting healing, protecting against infection, and supporting tissue regrowth. This partnership aims to strengthen MiMedx's position as a leader in the wound care market.
Craig-Hallum Adjusts MiMedx Group, Inc. (MDXG) Outlook on CMS Coverage Guidance
Craig-Hallum and Northland Securities have both lowered their price targets for MiMedx Group, Inc. (MDXG) following new CMS guidance affecting provider billing and local coverage determination for skin substitutes. This guidance is expected to cause provider confusion, pressure wound care volumes in Q1 2026, and extend the timeframe for market share gains. Despite near-term uncertainty, both firms maintain positive ratings, anticipating longer-term growth in wound care and surgical recovery segments.
Craig-Hallum Adjusts MiMedx Group, Inc. (MDXG) Outlook on CMS Coverage Guidance
Craig-Hallum recently lowered its price target for MiMedx Group, Inc. (MDXG) to $10 from $13 while maintaining a Buy rating, citing new CMS guidance that is expected to create provider confusion and pressure wound care volumes in Q1 2026. Northland Securities also reduced its price target to $10 from $12, attributing the adjustment to near-term uncertainty from CMS's flat-rate coverage for skin substitutes, despite anticipating long-term market share gains. MiMedx Group is a biomedical company specializing in placental tissue allografts for wound, surgical, and burn applications.
MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®
MIMEDX is celebrating the 15th anniversary of its placental allografts, EPIFIX and AMNIOFIX, which are used in wound care and surgical recovery. These products are recognized as the industry's most studied placental allografts, appearing in nearly 100 clinical and scientific publications, including seven randomized controlled trials. MIMEDX aims to continue its leadership in providing healing solutions through innovation.
Wound and surgical grafts behind nearly 100 studies hit 15 years
MIMEDX (MDXG) is celebrating the 15th anniversary of its placental allografts, EPIFIX and AMNIOFIX, which are used in wound care and surgical recovery. These products are featured in nearly 100 clinical and scientific publications, including seven randomized controlled trials, making them the industry’s most studied placental allografts. The company highlighted their broad clinical use across over a dozen surgical specialties and expressed gratitude to employees for their contributions to this milestone.
MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®
MIMEDX is celebrating the 15th anniversary of its placental allografts, EPIFIX and AMNIOFIX, which are used in wound care and surgical recovery. These products are recognized as the industry's most studied placental allografts, with nearly 100 clinical and scientific publications, including seven randomized controlled trials. MIMEDX aims to continue its leadership in healing solutions through innovation.
Hussman Strategic Advisors Inc. Buys Shares of 252,000 MiMedx Group, Inc $MDXG
Hussman Strategic Advisors Inc. initiated a new position in MiMedx Group (NASDAQ:MDXG) during the third quarter, purchasing 252,000 shares valued at approximately $1.759 million. This acquisition gives Hussman Strategic Advisors Inc. about 0.17% ownership in the company. MiMedx Group recently exceeded Q3 earnings expectations, reporting an EPS of $0.15 against an estimate of $0.07, and revenue of $113.73 million.
MiMedx Group, Inc. (NASDAQ:MDXG) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
MiMedx Group, Inc. (NASDAQ:MDXG) shares have dropped 26% in the last month and 40% over the past year, despite a P/E ratio similar to the market average at 19.1x. The company's earnings decreased by 51% last year, yet analysts project a 25% annual growth over the next three years, outpacing the broader market's 12%. The article suggests that while the stock's plummeting price brings its P/E in line with the market, some shareholders remain skeptical of future forecasts given past performance.
MiMedx Group FY2027 EPS Forecast Cut by Northland Securities
Northland Securities has revised its FY2027 EPS estimate for MiMedx Group down to $0.20 from $0.45, which is below the current consensus of $0.30 per share. This adjustment comes despite MiMedx recently exceeding quarterly expectations with an EPS of $0.15 and revenue of $113.7 million. The company's stock currently trades around $5.33, holds a "Moderate Buy" analyst rating, and an average target price of $10.67, although some firms have reduced their targets to $10.
Northland Capmk Forecasts MiMedx Group Q1 Earnings
Northland Capmk has projected MiMedx Group's (NASDAQ: MDXG) Q1 2026 EPS to be $0.02, with full-year 2026 EPS estimated at $0.12, significantly below the current consensus of $0.30. Despite this, MiMedx Group recently beat Q3 estimates with an EPS of $0.15 and revenue of $113.73 million. The stock currently has a "Moderate Buy" consensus rating and an average target price of $10.67, even after some analysts trimmed their targets.
MiMedx Group (NASDAQ:MDXG) Given New $10.00 Price Target at Lake Street Capital
Lake Street Capital has reaffirmed its "buy" rating on MiMedx Group (NASDAQ:MDXG), despite lowering the price target from $12.00 to $10.00. This new target still implies a significant upside of 86.74%. The company recently exceeded quarterly earnings expectations, and a substantial portion of its stock is held by institutional investors, indicating strong market interest.
Recent 8.9% pullback isn't enough to hurt long-term MiMedx Group (NASDAQ:MDXG) shareholders, they're still up 70% over 3 years
MiMedx Group (NASDAQ: MDXG) shareholders have seen a recent 8.9% pullback and a 21% drop in the last month, but the stock is still up 70% over a three-year period. The company transitioned from a loss to profitability during this time, which is generally a positive indicator for share price. Despite insider buying, the article notes that future earnings will be critical, and recent performance reflects overall market challenges, with a 37% loss over the past year against a market gain of 18%.
MiMedx Group (NASDAQ:MDXG) Hits New 12-Month Low - Here's What Happened
MiMedx Group (NASDAQ:MDXG) shares recently dropped to a new 52-week low of $5.65 on heavy trading, closing at $5.7040 after a previous close of $5.88. Despite this decline, the company holds a "Moderate Buy" consensus rating from analysts with an average price target of $11. MiMedx reported strong Q3 results, beating earnings and revenue estimates, and maintains a solid financial position with a market capitalization of approximately $839 million and a P/E ratio of 20.98.
Investors Interested In MiMedx Group, Inc.'s (NASDAQ:MDXG) Earnings
MiMedx Group, Inc. (NASDAQ:MDXG) has a P/E ratio of 22.9x, which is higher than nearly half of US companies. Despite a recent decline in earnings of 51%, analysts forecast a 25% annual growth over the next three years, outpacing the market's 12% prediction. This strong growth expectation appears to be the primary reason for its elevated P/E ratio, suggesting investors are optimistic about its future prospects.
Investors Interested In MiMedx Group, Inc.'s (NASDAQ:MDXG) Earnings
MiMedx Group, Inc. (NASDAQ:MDXG) has a P/E ratio of 22.9x, which is higher than nearly half of U.S. companies. Despite recent poor earnings performance, analysts predict a 25% annual earnings growth for MiMedx over the next three years, compared to the market's 12%, justifying its high P/E ratio for investors who anticipate a more prosperous future for the company. The article warns that investors should be aware of risks and consider if MiMedx offers a better investment opportunity.
MiMedx Group Inc Is Quietly Going Off: Is MDXG the Sleeper Stock You’re Sleeping On?
MiMedx Group Inc (MDXG) is gaining attention as a potential biotech comeback story, focusing on advanced wound care and tissue-based products. While the company has a background of lawsuits and is currently undergoing a turnaround, it is generating buzz on financial social media platforms as a niche recovery play. Investors are advised to consider its real business value in regenerative biologics against the inherent risks of the healthcare sector, including regulation and competition, before investing in this volatile small-cap stock.
MiMedx Group, Inc (MDXG) Stock Analysis: Exploring a Potential 92.73% Upside with Strong Buy Ratings
MiMedx Group, Inc. (MDXG) in the biotechnology sector shows strong growth potential with a current trading price of $6.33 and a market capitalization of $937.49 million. Analysts rate it a strong buy, expecting a 92.73% upside to an average target price of $12.20. The company boasts innovative products, robust revenue growth of 35.30%, and solid free cash flow, making it an attractive prospect for investors despite mixed technical indicators.
MiMedx Group Inc Is Quietly Going Off: Is MDXG the Sleeper Stock You’re Sleeping On?
The article discusses MiMedx Group Inc (MDXG) as a potential "sleeper stock" in the biotech sector, focusing on wound care and tissue-based products. It highlights the company's turnaround story, recent market momentum, and its appearance on trading watchlists. The author assesses the stock's price performance, underlying business, and risk-reward profile, concluding it's a selective play for informed traders interested in the biotech and regenerative medicine space.
Harbor Capital Advisors Inc. Cuts Holdings in MiMedx Group, Inc $MDXG
Harbor Capital Advisors Inc. significantly reduced its stake in MiMedx Group, Inc., selling 71.3% of its shares in Q3 and now owning approximately 0.23% of the company. Additionally, insider Kimberly Maersk-Moller also sold a substantial portion of her holdings. Despite these sales, MiMedx Group trades near $7 with a "Moderate Buy" consensus rating from analysts and a $11 average target price.
MiMedx Group, Inc. Partners with Regen Lab USA LLC to Distribute RegenKit®-Wound Gel in the U.S.
MiMedx Group, Inc. has entered an exclusive agreement with Regen Lab USA LLC to distribute RegenKit®-Wound Gel in the U.S., a product designed to treat chronic wounds. This partnership expands MiMedx's Advanced Wound Care portfolio with an FDA-approved, Medicare-covered autologous solution. The agreement positions MiMedx strongly for upcoming changes in Local Coverage Determination implementation, enhancing its competitive standing in the wound care market.
MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel
MiMedx Group, Inc. has announced an exclusive U.S. distribution agreement with Regen Lab USA LLC for their RegenKit®-Wound Gel. This fully autologous platelet-rich plasma and thrombin serum wound gel broadens MIMEDX's Advanced Wound Care portfolio. The kits, FDA-approved in 2022, are nationally covered for diabetic chronic wounds.
MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel
MIMEDX Group, Inc. has announced an exclusive U.S. distribution agreement with Regen Lab USA LLC for their RegenKit®-Wound Gel, an autologous platelet-rich plasma and thrombin serum wound gel. This agreement broadens MIMEDX's Advanced Wound Care portfolio with a differentiated autologous solution for chronic wounds, which is FDA approved and covered by CMS. The company expects this addition to strengthen its competitive position as new Local Coverage Determination guidelines are implemented in 2026.
MIMEDX to Host First Quarter 2025 Operating and Financial Results Conference Call on April 30
MiMedx Group, Inc. (Nasdaq: MDXG) announced it will report its first-quarter 2025 operating and financial results after market close on Wednesday, April 30, 2025. The company will host a webcast and conference call at 4:30 p.m. ET on the same day to discuss these results. Interested parties can access the call via webcast or phone.
MiMedx Group, Inc. Partners with Regen Lab USA LLC to Distribute RegenKit®-Wound Gel in the U.S.
MiMedx Group, Inc. has announced an exclusive agreement with Regen Lab USA LLC to distribute RegenKit®-Wound Gel in the United States, expanding its Advanced Wound Care portfolio. This FDA-approved wound gel, covered by Medicare, utilizes autologous platelet-rich plasma to treat chronic wounds. The partnership positions MiMedx strongly ahead of upcoming changes in Local Coverage Determination implementation in 2026.
MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel
MIMEDX Group, Inc. has announced an exclusive U.S. distribution agreement with Regen Lab USA LLC for their RegenKit®-Wound Gel. This fully autologous platelet-rich plasma and thrombin serum wound gel adds a differentiated option to MIMEDX's Advanced Wound Care portfolio and is covered nationally by CMS and LCD for diabetic chronic wounds. The agreement strengthens MIMEDX's competitive position as it expands its wound treatment offerings.
MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro
MIMEDX announced the publication of a study in the Journal of Inflammation detailing the immunomodulatory effects of its Purion® Processed Human Amniotic Membrane Allografts (DHACM and LHACM). The research highlights how these allografts regulate inflammatory responses, promoting efferocytosis and cell survival, which supports the healing cascade and tissue repair in complex wounds. This publication reinforces MIMEDX's commitment to scientific evidence and its position in the wound care market, particularly relevant for ongoing Local Coverage Determinations.
Lab study finds placental tissue grafts may help reset wound healing
MIMEDX (MDXG) announced a peer-reviewed publication in the Journal of Inflammation detailing in vitro findings for its Purion processed dehydrated (DHACM) and lyophilized (LHACM) human amnion chorion membrane allografts. The study indicates these allografts have multifactorial immunomodulatory effects on inflammatory monocytes and macrophages, enhancing pro-reparative functions like efferocytosis and cell survival. These findings suggest DHACM and LHACM have the potential to reset the wound-healing cascade in complex wounds characterized by persistent inflammation.
MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro
MiMedx Group, Inc. (Nasdaq: MDXG) announced the publication of a study in the Journal of Inflammation detailing the immunomodulatory effects of its Purion processed human amniotic membrane allografts (DHACM and LHACM). The research highlights how these products regulate inflammatory response and support the healing cascade, providing further scientific evidence for their clinical use in wound care. This publication reinforces MIMEDX's commitment to robust peer-reviewed research and strengthens its position in the marketplace.
MIMEDX reports immunomodulatory effects of placental allografts
MIMEDX Group, Inc. announced new research demonstrating the immunomodulatory properties of its placental allograft products, DHACM and LHACM, which regulate inflammatory cells and enhance pro-reparative functions crucial for chronic wound healing. The study's findings support the company's proprietary tissue processing methodology and clinical outcomes, with MIMEDX also showcasing strong financial performance and unanimous "Strong Buy" analyst ratings.
MiMedx Group, Inc. Announces New Research Supporting Immunomodulatory Effects of Amniotic Membrane Allografts
MiMedx Group, Inc. (Nasdaq: MDXG) has announced the publication of a new study in the Journal of Inflammation. This research supports the immunomodulatory effects of its dehydrated human amnion chorion membrane (DHACM) and lyophilized human amnion chorion membrane (LHACM) products, contributing to their comprehensive library of scientific and clinical evidence. CEO Joseph H. Capper highlighted the importance of this high-quality evidence, especially with evolving local coverage determinations and the products' ability to regulate inflammatory responses and promote healing in complex wounds.
MIMEDX Announces Publication in the Journal of Inflammation
MIMEDX announced the publication of an article in the Journal of Inflammation detailing the immunomodulatory effects of its Purion® Processed Human Amniotic Membrane Allografts (DHACM and LHACM). The in vitro study demonstrated that these allografts regulate inflammatory responses and enhance pro-reparative functions, which is significant for improving healing outcomes in complex and chronic wounds. This publication further strengthens MIMEDX's body of scientific evidence supporting its products.
